Type 2 diabetes is one of the chronic, debilitating diseases and distresses nearly 171 million people worldwide. Despite the availability of various medications and glucose measurement devices, glycaemic goals were not achieved in patients with diabetes. In this regard, new frontiers such as thiazolidinediones have demonstrated cardiovascular benefits in diabetes patients.

This exclusive KOL Interview explains the cardiovascular benefits of the new frontiers in diabetes management.